NCT03744104

A Clinical Trial of A Quadrivalent Influenza Vaccine

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Participants Aged Above 3 Years

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,688 (actual)
• Sponsor: Shanghai Institute Of Biological Products · Industry
• Sex: All
• Age: 3 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to assess the immunogenicity and safety of a quadrivalent influenza vaccine compared with a trivalent influenza vaccine in participants aged above 3 years.

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Quadrivalent influenza vaccine	0.5 mL, intramuscular, one dose
BIOLOGICAL	Trivalent influenza vaccine A	0.5 mL, intramuscular, one dose
BIOLOGICAL	Trivalent influenza vaccine B	0.5 mL, intramuscular, one dose

Timeline

• Start date: 2018-10-11
• Primary completion: 2019-10-08
• Completion: 2019-10-08
• First posted: 2018-11-16
• Last updated: 2024-01-02

Locations

2 sites across 1 country: China